000 | 02013 a2200589 4500 | ||
---|---|---|---|
005 | 20250517214812.0 | ||
264 | 0 | _c20190506 | |
008 | 201905s 0 0 eng d | ||
022 | _a1534-6080 | ||
024 | 7 |
_a10.1097/TP.0000000000002270 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aRodríguez-Perálvarez, Manuel | |
245 | 0 | 0 |
_aImpact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. _h[electronic resource] |
260 |
_bTransplantation _c12 2018 |
||
300 |
_a2056-2064 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xmortality |
650 | 0 | 4 | _aCase-Control Studies |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 |
_aEverolimus _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
650 | 0 | 4 |
_aLiver Neoplasms _xmortality |
650 | 0 | 4 |
_aLiver Transplantation _xadverse effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNeoplasm Recurrence, Local |
650 | 0 | 4 | _aProgression-Free Survival |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aGuerrero, Marta | |
700 | 1 | _aBarrera, Lydia | |
700 | 1 | _aFerrín, Gustavo | |
700 | 1 | _aÁlamo, Jose M | |
700 | 1 | _aAyllón, María D | |
700 | 1 | _aArtacho, Gonzalo Suarez | |
700 | 1 | _aMontero, José L | |
700 | 1 | _aBriceño, Javier | |
700 | 1 | _aBernal, Carmen | |
700 | 1 | _aPadillo, Javier | |
700 | 1 | _aMarín-Gómez, Luis M | |
700 | 1 | _aPascasio, Juan M | |
700 | 1 | _aPoyato, Antonio | |
700 | 1 | _aGómez-Bravo, Miguel A | |
700 | 1 | _aDe la Mata, Manuel | |
773 | 0 |
_tTransplantation _gvol. 102 _gno. 12 _gp. 2056-2064 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/TP.0000000000002270 _zAvailable from publisher's website |
999 |
_c28388056 _d28388056 |